A Phase 3 Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-Experienced Adults 50 Years of Age or Older (STRIDE-6).
Scott P, Haranaka M, Choi JH, Stacey H, Dionne M, Greenberg D, Grijalva CG, Orenstein WA, Fernsler D, Gallagher N, Zeng T, Li J, Platt HL; STRIDE-6 Study Group.
Clin Infect Dis. 2024 Dec 17;79(6):1366-1374. doi: 10.1093/cid/ciae383.
How to use antistreptolysin O titre.
Sen ES, Ramanan AV.
Arch Dis Child Educ Pract Ed. 2014 Dec;99(6):231-8. doi: 10.1136/archdischild-2013-304884. Epub 2014 Jan 30.
Antibody responses to capsular polysaccharide backbone and O-acetate side groups of Streptococcus pneumoniae type 9V in humans and rhesus macaques.
McNeely TB, Staub JM, Rusk CM, Blum MJ, Donnelly JJ.
Infect Immun. 1998 Aug;66(8):3705-10. doi: 10.1128/IAI.66.8.3705-3710.1998.
Single-chain variable fragment (scFv) targeting streptolysin O controls group A Streptococcus infection.
Aikawa C, Kawashima K, Fukuzaki C, Nakakido M, Murase K, Nozawa T, Tsumoto K, Nakagawa I.
Biochem Biophys Res Commun. 2021 Aug 20;566:177-183. doi: 10.1016/j.bbrc.2021.06.021. Epub 2021 Jun 12.
An anti-perfringolysin O monoclonal antibody cross-reactive with streptolysin O protects against streptococcal toxic shock syndrome.
Matsumura T, Nishiyama A, Aiko M, Ainai A, Ikebe T, Chiba J, Ato M, Takahashi Y.
BMC Res Notes. 2020 Sep 5;13(1):419. doi: 10.1186/s13104-020-05264-2.
Post-streptococcal uveitis.
Besada E, Schatz S, Saremi SS.
Optometry. 2000 Apr;71(4):233-8.
Antistreptolysin O; a study of this antibody in health and in hemolytic streptococcus respiratory disease in man.
RANTZ LA, RANDALL E, RANTZ HH.
Am J Med. 1948 Jul;5(1):3-23. doi: 10.1016/0002-9343(48)90003-5.
Human milk antibodies to global pathogens reveal geographic and interindividual variations in IgA and IgG.
Campo JJ, Seppo AE, Randall AZ, Pablo J, Hung C, Teng A, Shandling AD, Truong J, Oberai A, Miller J, Iqbal NT, Peñataro Yori P, Kukkonen AK, Kuitunen M, Guterman LB, Morris SK, Pell LG, Al Mahmud A, Ramakrishan G, Heinz E, Kirkpatrick BD, Faruque AS, Haque R, Looney RJ, Kosek MN, Savilahti E, Omer SB, Roth DE, Petri WA Jr, Järvinen KM.
J Clin Invest. 2024 Jun 11;134(15):e168789. doi: 10.1172/JCI168789.
Targeted amino acid substitutions impair streptolysin O toxicity and group A Streptococcus virulence.
Chiarot E, Faralla C, Chiappini N, Tuscano G, Falugi F, Gambellini G, Taddei A, Capo S, Cartocci E, Veggi D, Corrado A, Mangiavacchi S, Tavarini S, Scarselli M, Janulczyk R, Grandi G, Margarit I, Bensi G.
mBio. 2013 Jan 8;4(1):e00387-12. doi: 10.1128/mBio.00387-12.
Immunotherapy targeting the Streptococcus pyogenes M protein or streptolysin O to treat or prevent influenza A superinfection.
Herrera AL, Van Hove C, Hanson M, Dale JB, Tweten RK, Huber VC, Diel D, Chaussee MS.
PLoS One. 2020 Jun 23;15(6):e0235139. doi: 10.1371/journal.pone.0235139. eCollection 2020.
